Eli Lilly is reported to be in advanced negotiations to acquire Kelonia Therapeutics for a price in excess of $2 billion, according to people familiar with the matter. Those involved in the discussions indicated the companies could announce an agreement as soon as Monday, provided the talks do not break down.
The contemplated purchase price may not be limited to an upfront payment - the structure is said to potentially include additional payments tied to development or regulatory milestones.
Kelonia is a privately held biotechnology company developing a next-generation treatment for multiple myeloma, a form of blood cancer. The company is advancing a novel CAR-T therapy designed to reprogram a patients immune system to attack malignant cells. The approach under development emphasizes simplification, with the stated goal of avoiding both chemotherapy and the complex cell-manufacturing processes typically associated with CAR-T therapies.
Financially, Kelonia has raised just under $60 million to date. The firms most recent valuation, recorded in 2022, was slightly above $100 million.
For Eli Lilly, acquiring Kelonia would reinforce its position in the blood cancer segment and broaden its oncology pipeline. The reported discussions come amid an active period of dealmaking for Lilly, which has been pursuing acquisitions supported by strong cash flows from its high-selling weight-loss and diabetes medications.
Context and implications
While details of any definitive agreement remain subject to negotiation, the elements disclosed so far highlight three themes: a significant headline price above $2 billion, possible contingent milestone payments that would tie future payouts to clinical or regulatory progress, and a strategic fit related to CAR-T therapies for multiple myeloma. Because Kelonia is privately held and has raised limited capital relative to the reported purchase price, the transaction would represent a substantial valuation uplift compared with its last recorded value in 2022.
Market participants and industry observers will likely watch for confirmation of the announced timing and for any specifics on payment structure and governance, should a deal be finalized.